Ironwood Pharmaceuticals to Highlight Clinical and Preclinical Data for Praliciguat at the American Diabetes Association’s 78th Scientific Sessions
https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Highlight-Clinical-and-Preclinical-Data-for-Praliciguat-at-the-American-Diabetes-Associations-78th-Scientific-Sessions/default.aspx
Ironwood Pharmaceuticals to Highlight Clinical and Preclinical Data for Praliciguat at the American Diabetes Association’s 78th Scientific Sessions
https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Highlight-Clinical-and-Preclinical-Data-for-Praliciguat-at-the-American-Diabetes-Associations-78th-Scientific-Sessions/default.aspx
Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease
https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Announces-FDA-Orphan-Drug-Designation-for-Olinciguat-for-the-Treatment-of-Sickle-Cell-Disease/default.aspx
Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease
https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Announces-FDA-Orphan-Drug-Designation-for-Olinciguat-for-the-Treatment-of-Sickle-Cell-Disease/default.aspx
Ironwood Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Present-at-the-Goldman-Sachs-39th-Annual-Global-Healthcare-Conference/default.aspx
Ironwood Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Present-at-the-Goldman-Sachs-39th-Annual-Global-Healthcare-Conference/default.aspx
Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week® 2018
https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Presents-IW-3718-Data-Showing-Improvements-in-Heartburn-and-Regurgitation-Symptoms-in-Patients-with-Persistent-GERD-at-Digestive-Disease-Week-2018/default.aspx
Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week® 2018
https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Presents-IW-3718-Data-Showing-Improvements-in-Heartburn-and-Regurgitation-Symptoms-in-Patients-with-Persistent-GERD-at-Digestive-Disease-Week-2018/default.aspx
Ironwood Pharmaceuticals Announces Results of 2018 Annual Meeting of Shareholders
https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Announces-Results-of-2018-Annual-Meeting-of-Shareholders/default.aspx
Ironwood Pharmaceuticals Announces Results of 2018 Annual Meeting of Shareholders
https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Announces-Results-of-2018-Annual-Meeting-of-Shareholders/default.aspx